课题基金 / 基金详情

Molecular adn Chemical Biology of Integrated ER Stre

Molecular adn Chemical Biology of Integrated ER Stre
综合内质网应激的分子与化学生物学
批准号:
7843520
负责人:
BERTAL H. AKTAS
金额:
$17.37万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-15 至 2011-04-30

项目摘要

项目成果

BERTAL H. AKTAS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The ultimate goal of this application is the development chemical and genetic probes by high throughput screening assays for the study of endoplasmic reticulum (ER) biology and elucidating the role of the integrated ER-stress response in the pathogenesis human diseases. The Endoplasmic reticulum (ER) is the site of folding and assembly for most proteins destined for secretion or sub-cellular compartments. Reverse genetic studies indicate that abrogation of the integrated ER-stress response is lethal. ER homeostasis is therefore highly regulated and the demand for protein synthesis and the capacity of ER to fold the newly synthesized proteins must be matched. Any mismatch between the folding capacity of the ER and the demand for new proteins causes the accumulation of unfolded proteins in the ER and triggers the integrated ER-stress response, which attempts to correct the imbalance by one of three distinct, but integrated routes. Disorders of integrated ER-stress response are implicated in the pathogenesis of many malignancies, including type I and type II diabetes, cancer, inflammation, and neurodegenerative disorders. Despite this importance and the broad spectrum of malignancies associated with disorders of integrated ER-stress response, neither the chemical nor molecular genetics of the integrated ER-stress response have been studied in a systematic manner. We therefore propose to identify chemical and genetic modifiers of integrated ER stress response, which will enable in vitro and in vivo studies of the ER, and will serve as a future platform for the development of pharmaceutical agents for the therapy of human disorders in which disregulation of integrated ER-stress response is implicated. We therefore propose to take advantage of our recently developed high throughput screening (HTS) assays, which interrogate different arms of the integrated ER-stress response. Specifically we will screen libraries of chemical collections and small interfering RNAs (siRNA) to identify chemical probes and siRNAs that modify three distinct arms of integrated ER-stress response. The chemical and genetic modifiers of integrated ER-stress response will be validated in secondary and counter assays. The chemical probes identified through this effort will be critical for elucidating the role of ER-stress in the normal physiology as well as in the genesis of malignancies in which perturbations of ER- homeostasis are implicated. These probes may also serve as lead compounds for the development of ER-stress modifiers for the treatment of human disorders. Similarly, the genetic modifiers of integrated ER stress identified through this effort ma b targets for the development of novel therapeutics. PUBLIC HEALTH RELEVANCE: Mismatch between the folding capacity of the ER and demand for folding new proteins causes accumulation of unfolded proteins in the ER which then triggers integrated ER-stress response to restore the ER-homeostais. Various physiological and pathological stimuli as well as genetic mutations or other aberrations that compromise the integrated ER-stress response are associated with or implicated in the pathogenesis of many malignancies including type I and type II diabetes, inflammation, and neurodegenerative disorders including Alzheimer's and Parkinson's disease. Despite the importance of integrated ER-stress response in the pathophysiology of many disorders, there are very few chemical and genetic modifiers of the integrated ER-stress response, that we propose to remedy by screening chemical and siRNA libraries in high throughput integrated ER-stress response assay we have developed.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.bmcl.2011.10.126
发表时间: 2012-01-01
期刊: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
影响因子: 2.7
作者: [Denoyelle, Severine, Chen, Ting, Chen, Limo, Wang, Yibo, Klosi, Edvin, Halperin, Jose A., Aktas, Bertal H., Chorev, Michael]
通讯作者: Chorev, Michael
DOI: 10.1158/1541-7786.mcr-16-0454
发表时间: 2017-08
期刊: Molecular cancer research : MCR
影响因子: --
作者: [Persaud L, Zhong X, Alvarado G, Do W, Dejoie J, Zybtseva A, Aktas BH, Sauane M]
通讯作者: Sauane M
Protein Synthesis Inhibitors as anti-T. Cruzi agents
  • 批准号:
    10043125
  • 项目类别:
  • 资助金额:
    $22.38万
  • 财政年份:
    2020
  • 负责人:
    BERTAL H. AKTAS
  • 依托单位:
Targeting Endoplasmic Reticulum Stress Response for Cancer Therapy
  • 批准号:
    8685183
  • 项目类别:
  • 资助金额:
    $34.47万
  • 财政年份:
    2011
  • 负责人:
    BERTAL H. AKTAS
  • 依托单位:
Targeting Endoplasmic Reticulum Stress Response for Cancer Therapy
  • 批准号:
    8883404
  • 项目类别:
  • 资助金额:
    $35.53万
  • 财政年份:
    2011
  • 负责人:
    BERTAL H. AKTAS
  • 依托单位:
Targeting Endoplasmic Reticulum Stress Response for Cancer Therapy
  • 批准号:
    8512672
  • 项目类别:
  • 资助金额:
    $34.05万
  • 财政年份:
    2011
  • 负责人:
    BERTAL H. AKTAS
  • 依托单位:
海外基金